However, reflecting MDS’ heterogeneous nature, MDS patients demonstrated a highly heterogeneous CD34+ composition with aberrancies, including reduced HSCs and lymphoid progenitors, that were also observed in some AML patients and controls. This evidence concerns the gene CD34 and myelodysplastic syndrome.